Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 30/100

Failure Rate

14.1%

182 terminated/withdrawn out of 1293 trials

Success Rate

83.2%

-3.4% vs industry average

Late-Stage Pipeline

36%

469 trials in Phase 3/4

Results Transparency

73%

655 of 900 completed trials have results

Key Signals

109 recruiting655 with results130 terminated52 withdrawn

Enrollment Performance

Analytics

Phase 3
352(36.1%)
Phase 1
248(25.4%)
Phase 2
221(22.7%)
Phase 4
117(12.0%)
N/A
30(3.1%)
Early Phase 1
7(0.7%)
975Total
Phase 3(352)
Phase 1(248)
Phase 2(221)
Phase 4(117)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (1293)

Showing 20 of 1293 trials
NCT06980480Phase 3Recruiting

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

Role: lead

NCT05509569Completed

A Survey of Icatibant in Pediatric Participants With Hereditary Angioedema

Role: lead

NCT07752108Phase 3Not Yet Recruiting

A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis

Role: lead

NCT06461533Recruiting

A Survey of Susoctocog Alfa (Genetical Recombination) in Participants With Acquired Haemophilia A

Role: lead

NCT07429942Not Yet Recruiting

A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Received Recombinant ADAMTS13 (rADAMTS13) as Part of the Early Access Program

Role: lead

NCT05626088Completed

A Study in Adults With Inflammatory Bowel Disease (IBD) Receiving Vedolizumab in the Patient Support Program (PSP) in Brazil

Role: lead

NCT06722235Phase 3Recruiting

A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Role: lead

NCT06948318Phase 3Recruiting

A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia

Role: lead

NCT06565078Recruiting

A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency

Role: lead

NCT05023382Completed

A Study of Teduglutide in Japanese People With Short Bowel Syndrome

Role: lead

NCT06577363Recruiting

A Survey of Maribavir Tablets in Participants With Cytomegalovirus Infection

Role: lead

NCT07204314Phase 3Recruiting

A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder

Role: lead

NCT07319845Phase 2Recruiting

A Study of TAK-226 for Anemia in Japanese Patients With Lower-Risk Myelodysplastic Syndromes

Role: lead

NCT07648030Phase 2Recruiting

A Study of Rusfertide in Japanese Adults With Polycythemia Vera

Role: lead

NCT07623161Phase 3Recruiting

A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib

Role: lead

NCT05341115Phase 4Completed

A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Role: lead

NCT05397431Active Not Recruiting

A Survey of Lanadelumab in Participants With Hereditary Angioedema

Role: lead

NCT07217301Phase 3Recruiting

A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer

Role: lead

NCT07286058Phase 3Recruiting

Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis

Role: lead

NCT06443502Phase 3Recruiting

A Study to Learn About the Safety of Vedolizumab and How Well it Works in Children and Teenagers With Active Chronic Pouchitis

Role: lead